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Abstract
Purpose: To showwhether subcutaneous repository corticotropin injection (RCI, Acthar®
Gel, a repository corticotropin injection, can be an effective potential therapeutic agent
for noninfectious retinal vasculitis.
Methods: Patients with active retinal vasculitis were followed with serial ultra-wide-
field fluorescein angiograms and treated with 80 units of subcutaneous repository
corticotropin injection twice weekly.
Results: Primary outcome of ≥50% improvement in response level (RL) for retinal
vasculitis and percent improvement in retinal vasculitis severity scoring (RVSS) by more
than one quartile (≥25%) at week 12 was met in 15 and 16 of the 30 total eyes,
respectively, including 1 eye with severe retinal vasculitis in each group. Complete
resolution of retinal vasculitis was seen in seven eyes with a mean time of 17.1 weeks.
Intraocular pressure elevation requiring therapy and cataract progression were noted in
two and three eyes, respectively. One patient stopped medication due to side effects
(injection site reaction).
Conclusion: Repository corticotropin injection was well-tolerated overall. Repository
corticotropin injection may be an effective therapeutic agent in the treatment of
noninfectious retinal vasculitis.
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Retinal vasculitis (RV) represents a group of
sight-threatening and typically stubborn forms
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of ocular inflammation which may affect retinal
arteries, veins, or capillaries. It can be potentially
detrimental to vision by way of occlusive or
nonocclusive mechanisms, leading to secondary
unilateral or bilateral findings of retinal ischemia,
macular edema, neovascular changes, retinal
detachment, vitreous hemorrhage, and secondary
glaucoma.[1, 2] Noninfectious RV may present alone
or as a manifestation of or an association with
a wide variety of other ocular inflammatory
diseases like idiopathic intermediate, posterior,
and panuveitis or even potentially severe systemic
conditions such as sarcoidosis and Adamantiades-
Behçet’s disease.[1, 3]
The anatomy of the eye is such that examination
allows for direct visualization of retinal vasculature,
allowing one to observe and perform imaging of
in vivo vascular structures during the course of
active disease as well as response to employed
therapeutic measures. Findings suggesting RV
include directly visible measures such as retinal
sheathing, overlying inflammatory exudates,
segmental vascular narrowing, as well as
secondary signals of ischemia such as cotton wool
spots and intraretinal hemorrhages. Sometimes,
however, this inflammation is not detectable via
ophthalmoscopy alone. Fluorescein angiography
(FA) has long been the gold standard for imaging
and evaluation of RV and other related entities.
The availability of ultra-wide-field fluorescein
angiography (UWFA) now allows greatly improved
visibility and recognition of pathology involving the
retina and retinal vasculature, particularly in the
peripheral retina, and may also allow for imaging
through a small pupillary aperture.[4, 5]
Recommended therapeutic options for sight-
threatening noninfectious uveitis, as well as RV,
generally include anti-inflammatory regimens
involving corticosteroids in the short term
followed by steroid-sparing therapy utilizing
immunosuppressive medications, including
chemotherapeutic (disease-modifying anti-
rheumatic drugs or DMARDs) or biologic
agents.[2, 6–8] Novel means of addressing severe or
recalcitrant ocular inflammation have been studied
to give providers more options to choose from
when trying to reduce or eradicate inflammation
without relying on systemic corticosteroids.
Target molecules of more recently renewed
interest include melanocortin peptides such as
adrenocorticotropic hormone (ACTH), a key part
of the signaling involved in the hypothalamic–
pituitary–adrenal axis, and its cleavage product
alpha-melanocyte stimulating hormone (α-MSH).
ACTH is thought to help suppress inflammation
in part by a “steroid-dependent” mechanism
by causing upregulation of the endogenous
glucocorticoid in the adrenal cortices.[9, 10]
Other melanocortin, such as α-MSH, bind to
and activate separate melanocortin receptors
(MCRs) from ACTH, and have also been shown
to be instrumental in immune regulation in ocular
inflammatory diseases via a separate “steroid-
independent” mechanism.[11, 12] α-MSH has long
been known to contribute to ocular immune
regulatory mechanisms and immune privilege.[13]
In vitro studies have shown that α-MSH may
suppress both the innate and adaptive immune
response, and can induce the conversion of
effector T-lymphocytes into regulatory T-cells
(Tregs) which both suppress interferon-gamma
(IFN-γ) production and produce transforming
growth factor-beta (TGF-β).[14, 15] There are five
known human MCRs, one of which (MCR2)
exclusively binds ACTH and is responsible for
cortisol production. The other MCRs (MCR1, MCR3-
5) strongly bind α-MSH (and to a lesser degree β-
and γ-MSH) in various cells throughout the body
including several located in ocular tissues, notably
retina and retinal pigment epithelium, as well as
various leukocytes involved in both innate and
adaptive immunity.[16]
Repository corticotropin injection (RCI, Acthar®
Gel) is a naturally sourced complex mixture of
adrenocorticotropic hormone analogs and other
pituitary peptides. A major component in the
formulated complex mixture is N-25 deamidated
porcine ACTH (1-39). Per the label, the major
component is N-25 deamidated ACTH. If needed,
you may further expand the description with
the following: “The Acthar Gel manufacturing
process converts the initial porcine pituitary
extract with low ACTH content into a mixture
having modified porcine ACTH and other related
peptide analogs solubilized in gelatin. A major
component in the formulated complex mixture
is N-25 deamidated porcine ACTH (1-39). RCI is
known to bind to and activate all five MCRs in
humans. It has an indication for and has been
used to treat several systemic immune-mediated
diseases including rheumatoid arthritis, systemic
lupus erythematosus, sarcoidosis, and multiple
sclerosis, and also has an FDA indication for
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treating severe acute and chronic allergic and
inflammatory processes involving the eye and its
adnexa. Because of its unique mechanism, RCI
represents a novel approach to treating ocular
inflammatory disease, including disease that may
be refractory to other forms of therapy. More
recent data, unfortunately, on the use of RCI in
treating ocular inflammation is currently limited
only to case reports.
The purpose of this study is to further evaluate
the possible effectiveness of RCI in treating
patients with retinal vasculitis who may either be
treatment naïve or who have failed other forms of
therapy. It is the hypothesis of the authors that use
of RCI in these patients may lead to improvement
in markers of inflammatory activity on examination
and imaging, and potentially to resolution of active
inflammation altogether.
METHODS
Study Setting and Patient Population
This was a prospective, nonrandomized, open-
label, proof-of-concept study conducted at a
single, tertiary care uveitis center. Patients with
active retinal vasculitis as a manifestation of
noninfectious ocular inflammatory disease were
identified during routine follow-up care and invited
to participate. The inclusion criteria for the study
were: adult patients aged ≥18 years with active
retinal vasculitis (involving arteries, capillaries,
or veins) with a visible fundus via wide-field FA
in the study eye and willingness to participate.
The exclusion criteria included: patients who
were currently pregnant; active infectious ocular,
extraocular, and/or systemic disease; history of
malignancy (with the exception of dermatologic
entities of basal or squamous cell carcinoma
which have been excised); systemic illness
involving abnormalities of the hypothalamic–
pituitary–adrenal axis; primary adrenocortical
insufficiency or adrenocortical hyperfunction;
known hypersensitivity to study drug and/or
diagnostic tools; other severe disease that
warrants critical attention and renders patients
unable to participate in the study; retinal disease
that may confound or obfuscate findings of
retinal vasculitis (i.e., retinal vascular occlusion,
significant diabetic retinopathy), and no visible
fundus on dilated fundoscopy. Patients were
not enrolled if they had been treated with any
oral, periocular, or intraocular suspension of
corticosteroid within six weeks prior to the study;
any intraocular dexamethasone corticosteroid
implant within six months prior to the study; or any
long-lasting fluocinolone corticosteroid implant
within three years prior to the study. Additionally,
patients already prescribed and adherent to non-
steroidal immunosuppressive therapy continued
their regimens throughout the study, but no
modification of dose (increase or decrease) was
permitted within six weeks of initiating the trial
and throughout the duration of the treatment
and follow-up periods. Exceptions for changes
in concomitant medications were only made for
any patient that was deemed in need of rescue
therapy by the investigator at any time during
the study because of continued significant active
disease despite study medication use, or if there
was deemed poor tolerance of the medication
and the patient required additional therapy to help
control inflammation – these patients were then
excluded from further analysis of clinical response
of ocular inflammation to RCI.
Safety data were extracted from all patients
who had at least one follow-up visit after starting
medication. The per protocol population (PPP) was
defined by eyes of patients who were able to
participate in the study without deviation from
protocol for any portion of the study after the
initial visit, and data extracted from the PPP was
only utilized from visits for which strict adherence
to the study protocol was maintained without
deviation. Deviations from study protocol included
introduction of additional anti-inflammatory or
immunomodulatory therapy, stoppage of the study
medication, or any other reason for which the
participant was no longer deemed appropriate by
the investigator to include in the study prior to study
completion.
Institutional Review Board approval was
obtained prior to the initiation of the study.
The study was conducted in accordance with
the Declaration of Helsinki and adhered to Good
Clinical Practice guidelines. The clinical trial was
registered and can be found at ClinicalTrials.gov
identifier: NCT03066869. Each subject signed an
informed consent before participating in the study.
Definition of Response Level
Response level (RL) was defined at each visit as
predefined percentage changes in retinal vasculitis
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activity versus baseline activity at the initial visit,
with positive RL values indicating a reduced level
of activity or a positive response while on therapy,
and negative RL values indicating an increased
level of activity or a negative response while
on therapy. Active retinal vasculitis status was
defined as angiographic leakage on wide-field
FA from retinal arteries, capillaries, or veins, as
determined by one of the three investigators at
the time of baseline and subsequent visits. RL
scores used in data collection were determined
after study completion by two of the investigators
(SDA and PYC) independently assessing imaging
without referencing other clinical data from the
visits. RLs were graded in steps of either 0, 12.5
(1–12.5), 25 (13–25), 50 (26–50), 75 (51–75), or 100
(76–100) percent for improvement; if worsening
occurred, the samewas donewith a negative score
given. Scores were later compared for possible
discrepancy in grading, and if any were found,
an acceptable score was then agreed upon by
both investigators by utilizing the historical clinical
impression of the investigator at the time of each
visit.
Retinal Vasculitis Severity Scoring
To describe RV severity, retinal vasculitis severity
scoring (RVSS) was performed at the baseline,
week-12, and week-24 visits. The scoring system
was based on five sections, including an area
2.5 to 3 disc diameters surrounding the fovea
incorporating the temporal arcades designated
as the macula, and then diagonal separation
of the superior, nasal, inferior, and temporal
peripheral quadrants outside the arcades. Each
section received a score of 0 to 3 based on
the severity of leakage in the late angiographic
phase (venous phase). Macular scoring was based
on small vessel or capillary leakage in macular
quadrants: 0 for no leakage, 1 for one quadrant,
2 for two to three quadrants, and 3 for all
four quadrants. Peripheral quadrant leakage was
scored thusly: 0 for no leakage, 1 for staining of
vessels with minimal leakage, 2 for more leakage
with distinct vascular margins, and 3 for more
leakage obscuring the vessel margins. Total score
initially of 1 to 15 was possible, and scoring
was tabulated with retinal vasculitis severity score
given as thus: mild for score 1 to 5, moderate
for 5.5 to 10, and severe for 10.5 to 15. This
scoring was applied by two investigators (SDA and
PYC) independently assessing imaging without
referencing other clinical data from the visits
separately from the assessment of RL. These
values were then averaged for a final score at each
time point. Baseline-visit measurements were used
in the initial description of retinal vasculitis severity.
For comparison to the RL scoring previously
described, the week 12 and week 24 RVSS
were individually divided by the baseline RVSS,
and these numbers were then subtracted from 1
and multiplied by 100 to give an RVSS percent
improvement (or worsening if negative) in each
subject frombaseline. Of note, noworsening above
a score of 15 was possible, limiting this method
in this direction, however, this problem was not
encountered.
Data Collection
Patients were seen at baseline, as well as
subsequent visits occurring at weeks 2, 4, 8,
12, and 24 after initiation of RCI, with unscheduled
visits permissible if necessary. Study medication
for all patients was started within two weeks
following the baseline visit. Data collected
included best-corrected visual acuity (BCVA),
intraocular pressure, slit lamp biomicroscopy
findings, dilated fundus examination, wide-field
FA, weight, vital signs (blood pressure and heart
rate), and laboratory assessments. Macular imaging
via spectral domain optical coherence tomography
(OCT) was obtained per investigator initiative.
Biomicroscopic findings included anterior chamber
(AC) cell and flare as well as vitreous cell and haze
as scored per SUN criteria.[17] All assessments were
repeated at each visit after baseline, apart from
laboratory assessments, which were carried out at
weeks 4, 12, and 24 only to assess for potential
toxicity to medication.
WFA was performed for the study eye. Fundus
photography, red-free photographs, and fundus
autofluorescence were all completed prior
to intravenous injection of fluorescein dye.
Photographs were taken immediately at dye
injection, then every 10 s in the study eye followed
by alternate eye, for up to 30 s. Subsequently,
photographs were captured every 30 s in the
study eye, followed by the fellow eye for up to
2 min following the dye injection, then once per
minute in the study eye, followed by the fellow
eye for up to 7 min following the dye injection.
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OCT was performed at initial assessment visit
for most patients and then as needed; central
macular thickness (CMT) was reported for patients
if available.
Study Outcome Measures
The primary outcomemeasure was the percentage
of PPP eyes that improved during the study: (1)
eyes that had ≥50% improvement by definition in
RL by the week-12 visit or (2) eyes with RVSS that
improved by more than one quartile (>25%) by
week 12.
Secondary outcomes included numeric RVSS at
baseline, week 12, and week 24. Other secondary
outcomes were vision, intraocular pressure, AC cell
and flare, vitreous cell and haze, weight, blood
pressure, and heart rate. CMT was collected via
OCT for most patients, and follow-up OCT was
obtained for patients with cystoid macular edema,
which was defined as baseline CMT of 300 or more
or demonstrable intraretinal fluid.
Safety assessments, including drug tolerability,
adverse events, and all other ocular and/or
systemic complications were also evaluated.
Side effects of RCI and reasons for therapy
discontinuation were gathered.
Treatment Protocol
RCI was initiated at 80 units given subcutaneously
twice weekly after the baseline visit. Any changes
made in the treatment regimen during the study
resulted in the patient and eye(s) to no longer
be included in the PPP at any subsequent visits.
Patients who did not show clinical or objective
evidence on the assessment of improvement
while taking therapy were rescued at 12 weeks;
patients who showed worsening or concern for
their condition prior to 12 weeks were also rescued
with appropriate therapy at the discretion of the
investigator. Participants that were rescued were
also followed through 24 weeks.
Statistical Analysis
Categorical variables were described as counts
and percentages. Continuous variables were
described as means, standard deviations, and
ranges. Statistical analysis was performed with R
Statistical Package (version: 3.5.2). Categorical
variables were compared at each follow-up visit
with the one before except the baseline and two
weeks using Chi-square and Fisher’s exact test. Q-
Q plot was used to examine the normal distribution
of quantitative variables. Linear random mixed
model was used to show the 24-week trends. In
the analyses, the correlation between two eyes
and the follow-up times (12- and 24 week) were
examined in an unstructured correlation matrix.
The repeated measures analysis of variance was
used to determine 24-week change of weight, HR,
systolic and diastolic pressures. The eye was the
unit of all calculations except for demographics
and systemic side effects, where the patient
was the unit of calculations. P-value ≤ 0.05 was
considered significant.
RESULTS
Twenty patients were originally recruited for the
study. One patient did not return after the first
visit and was thus excluded from any analysis.
Another patient (one eye) was excluded because of
shallow peripheral retinal detachment. Thirty-one
eyes in 19 patients were followed until at least the
second visit. Table 1 lists a summary of patients’
demographic information.
The mean length of time with known diagnosis
of retinal vasculitis prior to screening was 5.8
± 3.93 years (range, 0 to 13). Then mean time
since the onset of symptoms for current active
inflammation was 2.0 ± 2.31 months (range,
0 to 7); 9 of 19 patients (47.4%) had idiopathic
disease and 10 had an associated systemic
disorder; 3 (15.8%) had HLA-B27-associated
uveitis, 2 (10.5%) had multiple sclerosis, and 5
(26.3%) had sarcoidosis [Table 1]. At the time of
screening, 8 of the 19 patients (42.1%) were already
on some form of systemic anti-inflammatory or
immunosuppressive therapy – these medications
included mycophenolate mofetil, cyclosporine,
interferon beta-1a, methotrexate, adalimumab,
infliximab, sulfasalazine, and ibuprofen.
Table 2 demonstrates the comorbidities and/or
complications of inflammation in 19 patients at the
time of screening.
Table 2 presents the uveitis and characteristics
of retinal vasculitis. Examples of responses of RV in
various PPP eyes at weeks 12 and 24 are shown in
Figure 1.
Furthermore, 30 eyes of 18 patients with
active RV were included in the PPP. Fourteen
JOURNAL OF OPHTHALMIC AND VISION RESEARCH VOLUME 16, ISSUE 2, APRIL-JUNE 2021 223
Treatment of Retinal Vasculitis with RCI; Anesi et al
Table 1. Demographics – characteristics and baseline details
Patient demographics
Patients enrolled 20
Patients with ≥1 follow-up (patients [eyes]) 19 [31]
Patients followed per protocol (patients [eyes]) 18 [30]






Hispanic or Latin 2 (10.5)
South Asian 1 (5.3)
Patients with uveitis, n (%) 18 (94.7)





Mean time with uveitis prior to the study (yr) 5.8± 3.93
Mean time with active symptoms prior to the study (months) 2.0± 2.31
Patients with idiopathic disease, n (%) 9 (47.4)
Patients with systemic association, n (%) 10 (52.7)
HLA-B27 3 (15.8)
Multiple sclerosis 2 (10.5)
Sarcoidosis 5 (26.3)
Patients on systemic anti-inflammatory medication, n (%) 8 (42.1)




Glaucoma/ocular hypertension 6 (31.6%)
Cystoid macular edema 6 (31.6%)
Epiretinal membrane 2 (10.5%)
Peripheral retinal ischemia 1 (5.3%)
Papillitis 3 (15.8%)
of the eighteen patients (23 of the 30 eyes
[76.7%]) were able to continue RCI in the
PPP through 12 weeks. Nine of the eighteen
patients (14 of the 30 eyes [46.7%]) were then
able to continue RCI through the entirety of
the 24 weeks of the study without change in
protocol. Nine eyes (30.0%) did not continue
in the PPP past week 12 – three patients (five
eyes) due to ineffectiveness, one (two eyes)
due to noncompliance, and one (two eyes) due
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Table 3. Characteristics of retinal vasculitis and uveitis
Characteristics of retinal vasculitis eyes (n = 31) Total













Mean number of quadrants involved 2.97
Types of uveitis Total patients (n = 19)
Anterior uveitis 2 (10.5)
Intermediate uveitis 1 (5.3)
Posterior uveitis 2 (10.5)
Panuveitis 3 (15.8)
RV, retinal vasculitis
This was changed to retinal vasculitis (RV)
Table 4. Changes in retinal vasculitis scoring system (RVSS) and response level (RL) from baseline to week 12 and week 24.
P-value was < 0.001 for the 24-week change of study indices by repeated measures analysis of variance without applying
correlation between fellow eyes, as well as comparison of baseline and week 12, baseline and week 24, and weeks 12 and 24
with applying correlation between fellow eyes.
Baseline Week 12 Week 24
RVSS1 6.92 ± 3.83 5.19 ± 4.67 3.81 ± 4.68
RL2 (OS)3 (%) 0.00 ± 0.00 37.72 ± 31.50 61.06 ± 34.76
RL2 (SS)4 (%) 0.00 ± 0.00 59.82 ± 34.73 74.11 ± 34.13
1Retinal vasculitis scoring system; 2Response level; 3Objective scoring; 4Subjective scoring
Table 5. Other ocular parameters
Screening 12 weeks 24 weeks P-value*
BCVA (logMAR) 0.28 ± 0.22 0.22 ± 0.22 0.18 ± 0.22 <0.001
IOP (mmHg) 14.36 ± 4.48 14.64 ± 4.09 13.64 ± 4.95 <0.001
AC cell 0.57 ± 0.92 0.00 ± 0.00 0.07 ± 0.18 0.264
AC flare 0.00 ± 0.00 0.36 ± 0.74 0.14 ± 0.36 ND
Vitreous cell 0.04 ± 0.13 0.14 ± 0.23 0.11 ± 0.21 <0.001
Vitreous haze 0.25 ± 0.67 0.00 ± 0.00 0.29 ± 0.47 0.998
BCVA, best-corrected visual acuity; IOP, intraocular pressure; AC, anterior chamber; LogMAR, logarithm of the minimum angle of
resolution
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Figure 1. Fluorescein angiography of per protocol study eyes (A–F) demonstrating changes in retinal vasculitis and generalized
inflammation from week 0 (baseline) to week 12 to week 24. Of note, varying levels of improvement were seen, from mild to
moderate to complete resolution by week 24.
to side effects as well as needing additional
treatment.
Therapeutic Response – Retinal Vasculitis
The primary outcome of improvement in RL of
at least 50% or more [Figure 2], or improvement
in RVSS to at least the second quartile or more
at week 12 [Figure 3] was seen in 15 and 16 of
30 total eyes, respectively (50.0% and 53.3%),
and of the 23 eyes that were followed on the
study protocol without deviation to week 12,
respectively (65.2% and 69.6%). Changes in RVSS,
% improvement via RVSS, and RL between baseline
and week 12, between weeks 12 and 24, and
between baseline and week 24 were statistically
significant (p < 0.001) [Table 4]. Of the 15 who
improved in RL to 50% by week 12, 7 were
classified as having mild RV, 7 moderate, and
1 severe. Of the 16 who improved in RVSS to
the second quartile or more by week 12, 8 were
classified as having mild, 7 moderate, and 1 severe
RV.
Of all 30 PPP eyes, the number of eyes followed
in the study without deviation in protocol included
30 at week 2, 28 at week 4, 26 at week 8,
23 at week 12, and 14 at week 24. The mean
RL and RVSS along with percent improvement
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Figure 2.Comparison of response level (RL) between objective retinal vasculitis scoring system (A) and subjective retinal vasculitis
scoring system (B).
Figure 3. Mean RL for PPP eyes at each study visit after baseline.
in RVSS for PPP eyes at baseline, weeks 12
and 24 are shown in Figure 4. Time to any
improvement and time to 50% improvement in RL
in the total PPP eyes are demonstrated in Figure
5.
Moreover, 7 of the 30 eyes (23.3%; CI 12.3 to
45.9%) experienced complete resolution of disease
by RL at the end of RCI use. The mean time to
resolution was 17.1 weeks (range 12 to 24).
Therapeutic Response – Other Ocular
Parameters
Changes in the mean BCVA and intraocular
pressure for all PPP eyes from screening to
12 weeks, and to 24 weeks were statistically
significant (P < 0.001) [Table 5]. Percentages of PPP
eyes for measures of anterior and posterior uveitis
at each visit are shown in Figure 6.
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Figure 4. Percentage of PPP eyes with varying RL at each study visit after baseline.
Figure 5. Slit lamp characteristics showing (A) anterior chamber (AC) cells, (B) AC flare, (C) vitreous cells, and (D) vitreous haze at
each study visit.
OCT evaluation at screening occurred in 23 eyes
of 14 patients. CME was found in eight eyes of six
patients. Improvement in CMEwas seen in five eyes
(62.5%) of four patients during the PPP visits, with
complete resolution occurring in three eyes (37.5%)
of three patients during the PPP visits.
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Safety Measurements
Thirteen of the eighteen PPP (21 eyes) used
RCI throughout the entire 24-week course of
the study. One patient stopped RCI during the
study due to an adverse reaction (injection site
reaction), one due to compliance, and three due
to poor efficacy of medication. Nine of the thirteen
patients to complete the course (14 eyes) had
no change in therapy through the entire study,
while the other four of the thirteen received
additional systemic or local therapy to help control
inflammation. Other nonserious adverse events
felt to be attributable to the addition of RCI
to therapy in this study group were insomnia
(two patients), mood change (one patient), loss
of appetite (one patient), and dizziness with mild
nausea (one patient). No concerning changes in
laboratory values were found in any patient during
the study.
Themeanweight in PPP eyes at screening, week
12, and week 24 was 184.16 ± 48.83, 184.52 ±
49.90, and 189.31 ± 48.47 pounds, respectively
(p < 0.001). The mean heart rate in the same
group and time points was 79.78 ± 15.77, 78.33
± 13.89, and 78.56 ± 14.43, respectively (p =
0.484). Similarly, the systolic and diastolic blood
pressure (BP) were 136.56 ± 15.56 over 90.56
± 10.60, 130.22 ± 20.24 over 84.89 ± 8.62,
and 133.11 ± 21.26 over 84.22 ± 9.32 beats per
minute (BPM), respectively, (p < 0.001 for both
measures).
Four eyes of two patients were started on either
topical or oral IOP-lowering medications at some
point during the study. Four eyes of another two
patients had no changes made in therapy during
the study.
Three of the thirty PPP eyes (10%) found in two
patients had any recorded cataract progression
during the study. One patient had cataract surgery
in one eye between the week-12 and week-24
visits for worsening posterior subcapsular cataract
which was noted after the patient was not using
RCI reliably – of note, surgery was performed when
active uveitis was not seen on exam but only
leakage on UWFA was seen. The other two eyes
were in a single patient where one-step worsening
cortical changes were noted in both eyes at the
week-24 visit that were not present at the week-12
visit; the changes in this patient were not reported
to be symptomatic.
DISCUSSION
The results of this study suggest that RCI can
be effective in the treatment of patients with
retinal vasculitis of various etiologies. Our primary
outcome of improvement of 50% or more by week
12 was met in half the eyes studied and 65.2% of
the eyes of patients by RL method who were able
to continue the study medication without deviation
until week 12, including an eye with severe
vasculitis. In addition, our separate and more
traditionally designed scoring method, or RVSS,
which was based on tabulation of defined features
in various cross-sections of UWFA imaging, yielded
percentages of eyes with the primary outcome for
improvement in scoring that were similar at 53.3%
and 69.6%, respectively at week 12. And while
there is no standard accepted method to evaluate
retinal vasculitis severity nor response to therapy,
the consistency seen with these separately applied
methods may demonstrate they both could be
viewed as reasonable means of evaluating RV for
the purposes of this study.
There was also a statistically significant
progressive increase in RL seen in eyes of
patients who maintained the study protocol
without deviation, despite the number of PPP
patients decreasing through the trial period as
would be expected in a proof of concept study
[Figures 2 and 3; Table 4]. This is an important point
to highlight, as it is the aim of the authors to show
whether there is significant potential (>25%) for
therapeutic benefit with use of this medication for
a difficult-to-treat and variably presenting disease
process such as retinal vasculitis. Rapid onset of
improvement (≤2.9 weeks) was also observed in
this study.
Furthermore, 23 of the 30 (76.7%) eyeswere able
to make it to the week-12 visit without a deviation
in study protocol for reason of adverse reaction or
need for more therapy before this time point, which
we argue is widely agreed upon as a sufficient
amount of time to allow any therapeutic measure to
show efficacy when evaluating whether response
is acceptable to continue the current course or
whether a change in therapy is required. It is also
notable that almost one third of eyes experienced
complete remission of disease by RL score by the
end of RCI use in this relatively short study time
period of 24 weeks, occurring by a mean of only
17.1 weeks of RCI use. The authors note that a
statistically significant increase in vitreous cell was
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noted between baseline andweek 12, however, the
differencewasminimal and fell below one standard
deviation.
Removal of initial use of corticosteroid
concomitant with RCI employment also arguably
provides the benefit of decreasing risk of
potential adverse events with concomitant use
of medications having similar side-effect profiles.
And while there is no guarantee that patients in
this study may have fared better or worse without
the introduction of RCI, it is arguable that a direct
response to therapy could be a more reliable
outcome measure than return in inflammation after
corticosteroid therapy is withdrawn.
RCI appeared to be well tolerated, stopped
in only one patient because of the side effect
attributable to the medication itself, an injection-
site reaction. It is worth noting that this type of
reaction may possibly be seen more frequently
in patients who do not allow the medication to
adjust to room temperature prior to withdrawal
from the vial and injection (as is intended by the
manufacturer). General side effects were minimally
seen and tolerated by patients without causation
alone for termination of study medication use.
A significant increase in mean weight of almost
5 pounds was seen when comparing the PPP
patients at week 24 to their screening visit, but no
significant gain was seen in the larger amount of
PPP patients at week 12 to their screening visit.
This could suggest that weight gain, albeit modest
in this case, is a potential side effect of RCI and
is more likely to manifest after use for more than
three months, which then has implications for any
potential long-term use of this medication. The
effect of medication on systolic blood pressure,
diastolic blood pressure, and heart rate was not
significant; however, this is only relatable to short-
term employment of RCI.
A study by Aggarwal and colleagues assessed
the safety and efficacy of RCI for treatment of
10 patients with polymyositis and dermatomyositis
utilizing the same dose and schedule over 24
weeks, however, subjects were not only allowed
to concomitantly utilize corticosteroid but also
to increase by 10 mg as a rescue and remain
in the study as needed.[18] Nonserious adverse
events were noted and more plentiful in this
group than in our study (22 vs 5) with only
half the participants, and serious adverse events
were seen including avascular necrosis leading
to hip arthroplasty and disseminated zoster with
pneumonitis requiring hospitalization. The higher
number of side effects including serious side
effects such as avascular necrosis might be due
to concomitant employment of oral corticosteroid
with RCI; however, this hypothesis should be
examined with more potent and long-term studies.
Interestingly, they saw a similar gain in weight
in their patients of approximately 5.72 pounds
over 24 weeks, however, the change was not
found to be significant. Again, we suspect that
higher rates of reactions or adverse events may be
found in patients who concurrently use systemic
corticosteroids and RCI together, due to the
partial mechanism of action in the latter and the
similarly described potential side effect profile of
each.
No clinically significant increase in IOP
measurements was seen over the course of
the study – although the mean IOP did statistically
increase by 0.28 between baseline and week
12, this was much less than 1 mmHg and fell well
within one standard deviation. The mean IOP then
fell below the baseline level at week 24 but again
this was less than 1-mmHg difference and much
less than the standard deviation. Despite the small
sample size, these findings over 24 weeks seem
to suggest significant or concerning elevation of
IOP is uncommon with RCI use.
Retinal vasculitis is well known to be a severe
type of ocular inflammation that is often refractory
to conservative (or even some aggressive)
therapeutic measures. Several case reports
and retrospective reviews have been published
describing varying efforts to treat noninfectious
retinal vasculitis, and any associated ocular
inflammatory disease, that had previously been
poorly responsive to other forms of therapy.
Vallet and colleagues showed anti-tumor necrosis
factor (TNF) agents, specifically adalimumab and
infliximab, to be effective in treating RV associated
with Behçet’s disease in 124 patients, with either
>50% improvement in RV or some improvement
along with significant reduction of systemic
corticosteroid seen in 90 and 94.9%, respectively,
after six months of therapy; they also noted that
infliximab was more often used for patients with
severe ocular disease, which included RV.[19]
Similarly, Sharma and colleagues reported 88.23%
of 60 patients with RV, associated with a large
variety of ocular inflammatory conditions, who
previously failed therapy with several conventional
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immunosuppressive medications and were later
treated with infliximab after which they were able
to attain clinical remission at six months after the
initiation of therapy, with 100% achieving remission
at 12 months.[20] A case of severe bilateral lupus-
associated panuveitis and RV was seen to worsen
despite pulse intravenous cyclophosphamide and
methylprednisolone and later improve only when
rituximab was added to these two medications.[21]
There are only two previously published case
reports of use of RCI in a patient with intraocular
inflammation – a patient with panuveitis and
diffuse RV, who had previously failed systemic
corticosteroid therapy and intravenous tocilizumab,
showing sustained improvement in disease activity
in this patient at the same dose used in this
study,[22] as well as a series of three patients with
bilateral, noninfectious anterior and intermediate
uveitis who showed improvement in inflammation,
stable vision, and ability to reduce mean systemic
steroid without any reportable side effects over 14
months of therapy.[23] These examples highlight
the importance of further investigation into newer
and possibly more effective means of treating
RV, such as RCI, especially considering some
patients may fail or have a contraindication or
adverse reaction to other known typically effective
medications.
To the best of our knowledge, this is the first
prospective study of patients with noninfectious
retinal vasculitis being treated with RCI. We
adapted a simple 15-point scale to assess RV
severity score and the clinical response via
calculation of improvement (or worsening) of this
score, which we feel is a feasible calculation that
can easily be made even in a clinical setting. We
also employed our own method to evaluate RV
activity as well as response to therapy for the
purpose of this study, as it is conceivably difficult
(and often confusing) to objectively measure levels
of a disease process that presents so variably, and
there is no widely accepted standardized method
in use for this form of ocular inflammation. Clinically,
retinal vasculitis is typically treated by observation
of overall response to therapy, thus we believe
subjective RL method to be easily translatable to
practice for those with familiarity for interpreting
FA. In finding a similar progression of score and
response to therapy via two independent methods,
we again feel this suggests that either of these
methods could be a valid means of following RV
severity and response to therapy.
There are several limitations to this study,
which include its open-label status, a limited study
period of only 24 weeks, the lack of a control
population, varied etiology and severity of disease,
concomitant use of other immunomodulatory
medications, as well as the use of patients either
on or off these other forms of therapy. As stated
above, the patient population represented a
variable group of disease processes that had
retinal vasculitis, as might be expected in a
condition or population being studied where
the number of patients is few. Criticism could
be made to this point of the validity of any
conclusions brought forth in this manuscript,
however, with the etiology of these processes
being at least agreeably noninfectious in nature,
the authors expect that these data contain
merit in the way of an observed response of a
noninfectious inflammatory process to a single
given therapy. Lastly, though this study was
performed with funding provided by “Mallinckrodt
Pharmaceuticals, Bedminster, NJ”, the authors
were solely responsible for protocol development,
initiation of patient recruitment, administration of
study protocol, as well as manuscript production.
In conclusion, given these findings, we therefore
recommend that RCI be considered as a potential
agent in the treatment of patients with RV at
a dose of 80U twice weekly, including patients
who have not responded to other types of anti-
inflammatory therapy. We also contend that the
use of prednisone need not be concurrent while
still seeing rapid benefit in this population with
tendency toward severe disease activity. These
findings should be evaluated with more potent
studies with larger sample sizes.
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